Stock futures rise slightly following Thursday’s wild ride

spike

People walk outside of the New York Stock Exchange.

Spencer Platt | Getty Images

U.S. stock futures opened higher on Thursday night after a volatile session in which the recent tech sell-off resumed.

Dow Jones Industrial Average futures were up by 76 points, or 0.3%. S&P 500 futures gained 0.3% along with Nasdaq 100 futures. 

The Dow ended the regular session down more than 1% along with the S&P 500. The Nasdaq Composite dropped 2%. All three of the major indexes had popped before closing lower.

That whipsaw action came as tech — the best-performing market sector year to date

Read More

Sandy Weill on Citigroup’s decision to name Jane Fraser its next CEO

spike

Former Citigroup CEO Sandy Weill told CNBC on Thursday that he was bullish about the bank’s future after it tapped Jane Fraser to be its next top executive, calling her a “natural leader” who can bring about future growth. 

“I’m thrilled that they chose a woman, but I’m more thrilled that they chose a woman who has done a phenomenal job over the last 16 years at Citi in just everything she’s ever had the opportunity to manage,” Weill, who remains a shareholder, said on “Closing Bell.”

Citigroup, the third-largest U.S. bank by assets, announced earlier Thursday that Michael Corbat 

Read More

Peloton, Oracle, Chewy & more

spike

Oracle CEO Safra Catz delivers a keynote address during the 2019 Oracle OpenWorld on September 17, 2019 in San Francisco, California. Oracle CEO Safra Catz kicked off day two of the 2019 Oracle OpenWorld with a keynote address. The annual convention runs through September 19.

Justin Sullivan | Getty Images

Check out the companies making headlines after hours Thursday:

Oracle — Shares of Oracle traded 2.3% higher on the back of fiscal first-quarter results that beat analyst expectations. The software giant posted a profit of 93 cents per share on revenue of $9.37 billion. Analysts expected earnings of 86 cents

Read More

FDA chief says he has ‘no intention’ of overruling career staff on decision

spike

FDA Commissioner Stephen Hahn testifies before the Senate Health, Education, Labor and Pensions (HELP) Committee hearing on Capitol Hill in Washington DC on June 30, 2020 in Washington,DC.

Kevin Dietsch | AFP | Getty Images

The head of the Food and Drug Administration on Thursday said he has “no intention” of overruling career scientists at the agency on an approval of a coronavirus vaccine even though he has the authority.

FDA Commissioner Stephen Hahn said any vaccine data released will be discussed publicly by an advisory committee of outside experts and that Peter Marks, who runs the FDA division that

Read More